仙琚制药(002332.SZ)：取得倍他米松磷酸钠注射液境内生产药品注册证书

Core Viewpoint - Xianju Pharmaceutical (002332.SZ) has received approval from the National Medical Products Administration for the registration of Betamethasone Sodium Phosphate Injection, indicating a significant milestone for the company in expanding its product portfolio in the corticosteroid market [1] Group 1: Product Approval - The company has been granted a Drug Registration Certificate for Betamethasone Sodium Phosphate Injection, with the certificate number 2026S00006 [1] - The injection is specified at a concentration of 4mg per 1ml, referencing the formulation of the EU-marketed Betamethasone Sodium Phosphate Injection, branded as Celestone® [1] - The product was originally developed by Schering-Plough, with the rights eventually transferred to Organon [1] Group 2: Market Context - Betamethasone Sodium Phosphate Injection is primarily used for diseases requiring glucocorticoid therapy [1] - The product has already been launched in several countries, including Belgium, Sweden, the Netherlands, Germany, France, and Poland, indicating its established presence in the international market [1]